Generic drug
Docetaxel price, strengths & recalls
Docetaxel has no weekly pharmacy acquisition cost. 7 manufacturers make it. It is in shortage (being discontinued). 2 recalls are ongoing. Its official label last changed on August 29, 2024.
Being discontinued2 open recallsGenericDocetaxel price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 10 mg/mL injection | Not priced this week | |||
| 20 mg/mL injection | Not priced this week | |||
Supply status: shortages & recalls
Shortages
- Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08)A business decision was made to discontinue manufacture of the drug.
- Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)A business decision was made to discontinue manufacture of the drug.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 8 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Docetaxel
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL INJECTION, for intravenous useInitial U.S. Approval: 1996
WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION
Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m2[see Warnings and Precautions (5.1)].
Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [see Warnings and Precautions (5.2)].
Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm3. Monitor blood counts frequently as neutropenia may be severe and result in infection [see Warnings and Precautions (5.3)].
Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to Docetaxel Injection or to other drugs formulated with polysorbate 80 [see Contraindications (4)]. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [see Warnings and Precautions (5.5)].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions (5.6)].
WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION
See full prescribing information for complete boxed warning.
•
Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m2 (5.1)
•
Avoid use of docetaxel if bilirubin > ULN, or if AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle (5.2)
•
Do not administer docetaxel to patients with neutrophil counts < 1500 cells/ mm3. Obtain frequent blood counts to monitor for neutropenia (4, 5.3)
•
Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy (5.5)
•
Contraindicated if history of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80 (4)
•
Severe fluid retention may occur despite dexamethasone (5.6)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA201525 · Sandoz
- First approved
- June 29, 2011 (15 years ago)
- Latest approved change
- September 21, 2023
- Approved label
- PDF, Sep 25, 2023
- Generic makers
- 3 approved generic applications on the market
Docetaxel questions
Is docetaxel in shortage?
Yes. 2 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has docetaxel been recalled?
8 recalls on record, 2 ongoing. Recalls name specific lots - check yours.
When did the docetaxel label last change?
The official label was last updated on August 29, 2024 (version 10). See what changed.
Talk about docetaxel
No comments yet. Questions, tips, what worked for you - start the conversation.